Phase 2 Trial Examines Gene-Expression Profiling for Cancer of Unknown Primary Site

View original article HERE. A randomized phase 2 trial examining the assignment of treatment based on gene-expression profiling compared with standard chemotherapy for patients with cancer of unknown primary site showed no improvement in the 1-year survival rate with the more tailored approach. However, several caveats may limit the relevance of the findings. A report […]

Read More

Artificial Intelligence Pilots in Community Oncology Yield Promising Results

A panel at the Community Oncology Alliance (COA) annual meeting (April 4-5, 2019; Orlando, FL) spoke to the evolution of artificial intelligence (AI) as well as the results of AI implementation in a few community practices. John Frownfelter, MD, FACP, chief medical officer, Jvion, began the session by elucidating some data trends in health care’s […]

Read More